Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS

Frontiers in Pharmacology

Pharmacology

Tirza Areli Calderón Boyle¹  Judi Kuplast¹  Gui Lan Ye¹  Amanda Golembesky²  Jeanne M. Schilder³ 

[1] GSK, Collegeville, PA, United States;GSK, Durham, NC, United States;GSK, Philadelphia, PA, United States;

关键词: niraparib;    PARP inhibitors;    pharmacovigilance;    FAERS;    lymphangioleiomyomatosis;   

DOI  :  10.3389/fphar.2023.1241524

 received in 2023-06-19, accepted in 2023-08-04,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Schilder, Golembesky, Boyle, Ye and Kuplast.